.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Moodys
Citi
Harvard Business School
Dow
Baxter
UBS
Healthtrust
Farmers Insurance
US Department of Justice

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: (3) and (6) substitued estrogenic compounds
Abstract:Novel estrogenic compounds of Formula I are provided. ##STR1## wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R.sub.1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R.sub.1 does not exist; R.sub.2 is lower alkyl; R.sub.3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R.sub.4 through R.sub.13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R.sub.14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R.sub.1 is hydroxy, the hydroxy or ester substituent may have either an .alpha. or a .beta. orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
Inventor(s): Hill; Edward N. (Wilmington, NC), Sancilio; Frederick D. (Wilmington, NC), Whittle; Robert R. (Wilmington, NC)
Assignee: Endeavor Pharmaceuticals (Wilmington, DE)
Filing Date:May 15, 2003
Application Number:10/438,585
Claims:1. A compound represented by the following Formula: ##STR8##

or a sodium salt, calcium salt, magnesium salt, lithium salt, or amine salt thereof.

2. The compound according to claim 1, wherein the compound has the following characteristics: having a peak located at about 1.2 ppm on a .sup.1 H-NMR; and having a peak located at about 45 ppm on a .sup.13 C-NMR.

3. A compound represented by the following Formula: ##STR9##

or a sodium salt, calcium salt, magnesium salt, lithium salt, or amine salt thereof.

4. The compound according to claim 3, wherein the compound has the following characteristics: having a peak located at about 1.2 ppm on a .sup.1 H-NMR; and having a peak located at about 45 ppm on a .sup.13 C-NMR.

5. A pharmaceutical composition comprising a compound represented by the following Formula: ##STR10##

or a sodium salt, calcium salt, magnesium salt, lithium salt, or amine salt thereof.

6. The pharmaceutical composition of claim 5, wherein the compound has the following characteristics: having a peak located at about 1.2 ppm on a .sup.1 H-NMR; and having a peak located at about 45 ppm on a .sup.13 C-NMR.

7. A pharmaceutical composition comprising a compound represented by the following Formula: ##STR11##

or a sodium salt, calcium salt, magnesium salt, lithium salt, or amine salt thereof.

8. The pharmaceutical composition of claim 7, wherein the compound has the following characteristics: having a peak located at about 1.2 ppm on a .sup.1 H-NMR; and having a peak located at about 45 ppm on a .sup.13 C-NMR.

9. The pharmaceutical composition according to claim 5, wherein the composition further comprises at least one additional pharmaceutically active ingredient.

10. The pharmaceutical composition according to claim 9, wherein the at least one additional pharmaceutically active ingredient is selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts, and vitamin D, and mixtures and combinations thereof.

11. The pharmaceutical composition according to claim 7, wherein the composition further comprises at least one additional pharmaceutically active ingredient.

12. The pharmaceutical composition according to claim 11, wherein the at least one additional pharmaceutically active ingredient is selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts, and vitamin D and mixtures and combinations thereof.

13. A method of treating mammals in need of estrogen therapy, said method comprising administering an effective amount of a compound represented by: ##STR12##

or a sodium salt, calcium salt, magnesium salt, lithium salt, or amine salt thereof.

14. A method of treating mammals in need of estrogen therapy, said method comprising administering an effective amount of a compound represented by: ##STR13##

or a sodium salt, calcium salt, magnesium salt, lithium salt, or amine salt thereof.

15. The method according to claim 13, wherein the compound at position C(17) has a .beta. orientation.

16. The method according to claim 13, wherein said compound is administered as part of a pharmaceutical composition, said composition further comprising at least one additional pharmaceutically active ingredient.

17. The method according to claim 16, wherein the at least one additional pharmaceutically active ingredient is selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts, and vitamin D and mixtures and combinations thereof.

18. The method according to claim 14, wherein said compound is administered as part of a pharmaceutical composition, said composition further comprising at least one additional pharmaceutically active ingredient.

19. The method according to claim 18, wherein the at least one additional pharmaceutically active ingredient is selected from the group consisting of estrogenic compounds, androgenic compounds, progestin compounds, vasodilation agents, calcium salts, and vitamin D and mixtures and combinations thereof.

20. The method according to claim 13, wherein the condition treatable by estrogen therapy is selected from the group consisting of vasomotor symptoms, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, hypoestrogenism due to castration, hypoestrogenism due to primary ovarian failure, breast cancer in selected persons with metastatic disease, advanced androgen-dependent carcinoma of the prostate, abnormal uterine bleeding, and kraurosis vulvae.

21. The method according to claim 14, wherein the condition treatable by estrogen therapy is selected from the group consisting of vasomotor symptoms, atrophic vaginitis, osteoporosis, hypoestrogenism due to hypogonadism, hypoestrogenism due to castration, hypoestrogenism due to primary ovarian failure, breast cancer in selected persons with metastatic disease, advanced androgen-dependent carcinoma of the prostate, abnormal uterine bleeding, and kraurosis vulvae.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Covington
Chinese Patent Office
Teva
Fish and Richardson
Medtronic
US Department of Justice
Accenture
McKesson
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot